Status:
RECRUITING
Investigation of Three Biomarkers for the Detection of Prostate Cancer
Lead Sponsor:
Medtechtomarket Consulting Ltd
Collaborating Sponsors:
GlycoscoreDx Ltd
Conditions:
Cancer of Prostate
Eligibility:
MALE
18+ years
Brief Summary
GlycoScore Dx Limited, a diagnostics company based in the United Kingdom have identified three glycoproteins, that showed promise as biomarkers of prostate cancer in initial validation studies. The pu...
Detailed Description
Worldwide, prostate cancer is the most commonly diagnosed cancer in men and the fifth leading cause of cancer death in men. This amounted to 1,414,249 newly diagnosed cases and 375,000 deaths worldwid...
Eligibility Criteria
Inclusion
- Male patients aged 18 years and over
- The patient is being investigated for suspected prostate cancer or is on active surveillance
- The patient is able to give consent to take part in the study
Exclusion
- A patient who has already taken part in the study
- A patient with an active urinary tract infection
- The patient has a prior diagnosis of any other cancer or is receiving any cancer treatment (including ADT)
- The patient is currently or within the last 4 months enrolled on another study involving an investigational medicinal product
Key Trial Info
Start Date :
January 7 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 7 2026
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT06554587
Start Date
January 7 2025
End Date
March 7 2026
Last Update
January 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Liverpool University Hospital
Liverpool, United Kingdom, L7 8XP